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Abstract 
Background: Early diagnosis of HIV associated lymphoma is challenging because the definitive diagnostic procedure 
of biopsy, requires skills and equipment that are not readily available. As a consequence, diagnosis may be delayed 
increasing the risk of mortality. We set out to determine the frequency and risk factors associated with the misdiagno‑
sis of HIV associated lymphoma as tuberculosis (TB) among patients attending the Uganda Cancer Institute (UCI).
Methods: A retrospective cohort study design was used among HIV patients with associated lymphoma patients 
attending the UCI, Kampala, Uganda between February and March 2015. Eligible patient charts were reviewed for 
information on TB treatment, socio‑demographics, laboratory parameters (Hemoglobin, CD4cells count and lactate 
dehydrogenase) and clinical presentation using a semi structured data extraction form.
Results: A total of 183 charts were reviewed; 106/183 were males (57.9%), the median age was 35 (IQR, 28–45). Fifty 
six (30.6%) patients had a possible misdiagnosis as TB and their median time on TB treatment was 3.5 (1–5.3) months. 
In multivariate analysis the presence of chest pain had an odd ratio (OR) of 4.4 (95% CI 1.89–10.58, p < 0.001) and 
stage III and IV lymphoma disease had an OR of 3.22 (95% CI 1.08–9.63, p < 0.037) for possible misdiagnosis of lym‑
phoma as TB.
Conclusion: A high proportion of patients with HIV associated lymphoma attending UCI are misdiagnosed and 
treated as TB. Chest pain and stage III and IV of lymphoma were associated with an increased risk of a possible misdi‑
agnosis of lymphoma as TB.
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Background
Worldwide, 35 million people were living with HIV at the 
end of 2013 [1]. Sub-Saharan Africa remains the most 
severely affected region, accounting for 71% of the people 
living with HIV [1]. In Uganda at least 130,000 HIV new 
infections occur every year [2]. In 2013, an estimated 1.6 
million Ugandans were living with HIV, and an estimated 
63,000 people died of AIDS-related illnesses [3] includ-
ing HIV related cancers. In the African setting Kaposi 
sarcoma remains the commonest AIDS related malig-
nancy and lymphoma has also increased due to HIV epi-
demic [4].
HIV increases the risk of lymphoma, especially non-
Hodgkin’s lymphoma (NHL) [5] resulting in it being cat-
egorized as an AIDS defining illness [6]. In Uganda the 
frequency of lymphomas particularly NHL, the more fre-
quent type has increased since the beginning of the HIV/
AIDS pandemic in the early 1980s [7]. The incidence of 
NHL among HIV infected individuals is 7.3 cases per 
100,000, being 6.7-fold higher compared to HIV unin-
fected persons [9]. The Kampala Cancer Registry reports 
the incidence of NHL in Kampala is increasing by 6.7% 
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annually in men and 11% annually in women since the 
beginning of the HIV pandemic.
A study done in Uganda showed that all HIV-positive 
Ugandans with NHL not receiving HAART die within 
1 year of NHL diagnosis [9]. NHL and other AIDS related 
lymphomas are typically more advanced at presentation 
[5]. The advanced stage III and stage IV lymphoma dis-
ease have been used in the international prognostic index 
(IPI) tool to predict survival in aggressive lymphoma in 
which are associated with poor survival rates. It is there-
fore paramount to have an early diagnosis and treatment 
of lymphoma before it presents with advanced stage III 
and IV disease. These diseases have nonspecific symp-
toms; commonly presenting with lymphadenopathy and 
constitutional symptoms of fever, weight loss and night 
sweats, and can also affect extra-nodal sites, giving rise to 
atypical presentations [9]. These symptoms mimic other 
HIV opportunistic infections like tuberculosis (TB) [10]. 
TB is the leading cause of morbidity and mortality in 
HIV with extra pulmonary TB (EPTB) on a rise in sub-
Saharan Africa. TB affects any part of the body resulting 
in a nonspecific clinical presentation depending on the 
organ of the body affected including fevers, night sweats, 
weight loss and lymphadenopathy.
Lymphoma diagnosis is challenging even for patholo-
gists in developed nations without hematopathological 
specialization [9]. The gold standard for the diagnosis 
of lymphoma is biopsy and histology. These are inva-
sive and limited by the need for skill and unavailability 
of pathology centers in many health centers. As a result 
diagnosis is missed and commonly HIV patients with 
lymphadenopathy and constitutional symptoms are usu-
ally empirically treated for TB resulting into delayed 
diagnosis of lymphoma [9] especially in rural settings. In 
a south African retrospective study, 18/21 patients with 
lymphoma had received anti-TB treatment in the preced-
ing 12 months before diagnosis of lymphoma was made 
[9]. This study had a small sample size limiting the inter-
pretation of the findings and it did not look at the fac-
tors associated with the misdiagnosis. In this study, we 
aimed to investigate the frequency and factors associated 
with lymphoma misdiagnosis as TB among a substantial 
population of HIV positive patients diagnosed with lym-




A retrospective cohort chart review was carried out 
between February and March 2015 at the Uganda Cancer 
Institute (UCI) in Kampala located in Mulago Hospital 
complex. UCI is a national cancer referral center receiv-
ing about 3000 new cancer patients annually. Majority of 
these patients are referred from Mulago National Refer-
ral and Teaching Hospital with a histological diagnosis 
which is then re-assessed at the UCI and biopsy sam-
ples reexamined. The Institute receives about 3–4 new 
patients with lymphoma every month according to local 
data. Charts of documented HIV infected patients who 
attended the UCI from January 2004 to November 2014 
with a histological diagnosis of lymphoma were reviewed. 
Patients were allocated into two arms, those with and 
without a history of TB treatment (Fig. 1). Patients charts 
who had a history of TB treatment more than 12 months 
prior to the diagnosis of lymphoma together with 
patients charts that had missing data on the history of TB 
treatment were excluded from the study.
Trained data clerks retrieved patient charts from the 
records department at UCI and extracted the required 
information into a standard data form. Blood investiga-
tions, (Hemoglobin, lactate dehydrogenase and CD4 cell 
count) and imaging (abdominal ultrasound and chest 
x-ray) were extracted. The age, sex, address, level of edu-
cation, clinical presentation of fevers, night sweats, lym-
phadenopathy and ascites were captured.
History of TB treatment was recorded within the last 
12  months prior to diagnosis of lymphoma, site of TB, 
duration on anti-TB’ treatment before diagnosis of lym-
phoma and the method of TB diagnosis to capture bac-
teriological versus empirical diagnosis of TB. Patients 
with a history of empirical TB treatment with no clini-
cal improvement who later got a histological diagnosis 
of lymphoma were considered a possible misdiagnosis 
(Fig.  1). Type and stage of HIV associated lymphoma 
were also recorded.
Statistical analysis
Data obtained was checked and entered using EPI-DATA. 
Analysis was performed using Stata version 13 Software. 
Frequency of TB misdiagnosis in patients with HIV asso-
ciated lymphoma was established as a proportion among 
No TB treatment prior to 
diagnosis of HAL (n=123)
221 HAL patients 
38 excluded due to missing TB data 
183 patients eligible 
TB treatment prior to 





Lymphoma/TB Co-infection (n=4)Misdiagnosis (n=56)
Fig. 1 Study inclusion criteria. TB tuberculosis, HAL HIV associated 
lymphoma
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the total HIV associated lymphoma patients studied. 
Categorical variables were summarized as percentages 
and frequencies while continuous variables were sum-
marized as median and interquartile range. To establish 
factors associated with misdiagnosis of TB in patients 
with lymphoma, bivariate analysis was performed using 
a Chi square test statistic for the categorical variables 
and a Wilcoxon rank-sum (Mann–Whitney) test for the 
numeric/continuous variables and those with a conserva-
tively set p value  <0.2 were analyzed using multivariate 
regression analysis. Variables with final p values  <0.05 




From February to March 2015; 221 clinical charts of 
HIV- infected patients with lymphoma attending the 
Uganda Cancer Institute were reviewed of which 38 were 
excluded because of missing data on TB treatment leav-
ing a total of 183 patient files.
There were 106/183 (57.9%) males; the median age 
was 35  years (IQR 28–45). Many of these participants 
had attained primary education 167/183 (91%). 91/183 
(49.7%) were married and 19/183 (10.4%) were widowed. 
Lymphadenopathy was the commonest presentation 
at 161/183 (91%) with chest pain at 44/183 (24.3%) and 
dyspnea at 43/183 (23.5%) being the least. The median 
CD4 cell count was relatively low, 232 cells/μl. Those who 
had received anti-TB were treated for a median time of 
3.5 (1–5.3) months before a histological diagnosis of lym-
phoma was made due to failure to respond to TB medica-
tion (Table 1). Of the 183 patients with lymphoma, NHL 
accounted for 119/183 (65%) and Hodgkin’s lymphoma 
(HL) was 64/183 (30%). Most patients 142/183 (77.6%) 
presented with advanced cancer, with mainly stage III 
and IV lymphoma, 7/183 (3.8%) had stage I lymphoma 
disease. Only 120 out of 183 (65.4%) patients were on 
highly active anti-retroviral therapy.
Sixty patients (32.8%) had history of TB treatment of 
which 56/183 (30.6%) had received empirical TB treat-
ment while 4/183 (0.02%) had treatment for bacterio-
logically confirmed TB. Majority of the patients with a 
history of TB treatment 51/60 (85%) had been treated 
for EPTB. The 56 patients [56/183 (30.6%)], with initial 
empirical TB treatment did not improve with TB treat-
ment, and were considered to have a possible misdiagno-
sis (Fig. 1; Table 2).
Comparison of characteristics between possible 
misdiagnosis and definite diagnosis
Table  3 shows the results of the bivariate analysis in 
which stage of lymphoma [OR 4.03 (95% CI 1.49–10.93, 
Table 1 Baseline Characteristics of HIV/lymphoma patients
Baseline characteristics n %
Gender (n = 183)
 Female 77 42.1
 Male 106 57.9
Marital status (n = 183)
 Divorced/separated 36 19.7
 Married 91 49.7
 Single 37 20.2
 Widowed 19 10.4
Occupation (n = 183)
 Casual laborer 39 21.3
 Civil servant 30 16.4
 House wife 33 18
 Peasant 41 22.4
 Trader 40 21.9
Education (n = 183)
 None 16 8.7
 Primary 80 43.7
 Secondary 63 34.4
 Tertiary 24 13.1
Fever (n = 183)
 No 37 20.2
 Yes 146 79.8
Chest pain (n = 181)
 No 137 75.7
 Yes 44 24.3
Cough (n = 183)
 No 116 63.4
 Yes 67 36.6
Drenching night sweats (n = 183)
 No 36 19.7
 Yes 147 80.3
Loss of appetite (n = 180)
 No 37 20.6
 Yes 143 79.4
Lymph node swelling (n = 177)
 No 16 9
 Yes 161 91
Dyspnea (n = 183)
 No 140 76.5
 Yes 43 23.5
Median (IQR)
Age (years) 35 (28–45)
HAART duration (months) 18 (5–18)
Duration on anti TB (months) 3.5 (1–5.3)
CD4 count 232 (124–387)
Body mass index 19.5 (17.1–21.6)
Hemoglobin 10.2 (8.4–12.1)
LDH value 462 (302–772)
HAART anti-retroviral therapy, LDH lactate dehydrogenase, IQR inter quartile range
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p  <  0.006)], dyspnea [OR 2.46 (95% CI 1.01–5.97, 
p < 0.01)], fever [OR 3.62 (95% CI 1.31–10.01, p < 0.016)], 
drenching night sweats [OR 4.41 (95% CI 1.45–3.37, 
p  <  0.008)], chest pain [OR 3.3 (95% CI 1.46–7.46, 
p  <  0.004)], hemoglobin level [OR 0.88 (95% CI 0.78–
0.99, p < 0.034)], ART status [OR 1.88 (95% CI 0.93–3.8, 
p < 0.070)] and loss of appetite [OR 4.17 (95% CI 1.51–
11.52, p  <  0.016)], were associated with possible lym-
phoma misdiagnosis as TB.
These variables were further used for multivariate 
analysis to determine the factors associated with possible 
misdiagnosis of HIV/lymphoma co infected patients as 
TB patients. The multivariate analysis shown in Table 4 
revealed chest pain and stage of lymphoma to be inde-
pendently associated with possible misdiagnosis of lym-
phoma aOR 1.46 (95% CI 0.41–5.23, p < 0.001) and aOR 
3.22 (95% CI 1.08–9.63, p < 0.04) respectively. The CD4 
count was excluded at multivariate analysis due to miss-
ing data. ART duration was excluded because not every 
study participant was on HAART.
Discussion
In our study we found three in every ten patients with 
HIV associated lymphoma attending UCI, had a possible 
misdiagnosis before a final diagnosis of lymphoma was 
made. These patients were treated for TB for a median 
period of 16 weeks prior to correct diagnosis. The WHO 
2003 TB treatment guidelines for national programmes 
suggest empirical TB treatment in HIV infected patients 
with symptoms of TB, stressing the importance of fol-
low-up investigations and reviews of treatment response 
after 1 month [11] to rule out other diseases that mimic 
TB. If followed as recommended, early review of treat-
ment response offers opportunities for earlier investiga-
tion and diagnosis of other diseases especially lymphoma 
that mimics TB in order to improve survival.
Majority of these patients were treated for EPTB, and 
therefore stand a high chance to be registered as EPTB 
treatment failures in national statistics and for this rea-
son, this high frequency of misdiagnosis of lymphoma as 
TB could be contributing to the low EPTB treatment suc-
cess rate of 66% reported by the WHO for Uganda [11].
Our study is the first to explore clinical symptoms and 
signs that are associated with possible misdiagnosis of 
TB among lymphoma patients. We found all patients in 
our retrospective cohort to be symptomatic with more 
than one constitutional symptom. Chest pain, stage of 
lymphoma, fever, HAART status, low hemoglobin, dysp-
nea, drenching night sweats and loss of appetite were 
the main factors found to be associated with TB misdi-
agnosis in bivariate analysis. Although many patients 
presented with lymphadenopathy, it was not found to be 
associated with misdiagnosis of Lymphoma. The risk of 
being initiated on empirical anti-TB treatment prior to 
the diagnosis of lymphoma was 4.4 times in cases where 
one had chest pain and 3.2 times in cases where one had 
stage III and IV lymphoma disease as compared to no 
chest pain and stage I and II lymphoma disease respec-
tively. This indicates that advanced lymphoma (stage III 
and IV) is symptomatically very similar to TB as chest 
pain is a common symptom in TB [9].
Our findings were somewhat different from the South 
African study with a lower frequency of misdiagnosis 
30.6% compared to theirs, 85.7% and shorter length of 
TB treatment prior to lymphoma diagnosis. These differ-
ences may be explained by a smaller sample size in the 
South African study of (21 patients) or the retrospective 
nature of the South African study although similar to 
ours, dealt with patients directly rather than data.
Worryingly our data also showed a low rate of ART 
(65.4%). Our study did not allow for CD4 count analy-
sis as it was not undertaken in the HIV clinic setting, 
however, a lymphoma diagnosis gives a patient an HIV 
WHO stage of IV which necessitates ART initiation. Ear-
lier work in Uganda shows that mortality in those with 
lymphoma and HIV not on ART is 100%. HIV and can-
cer specialists should consider strategies that increase 
communication for patient care, such as the integrated 
HIV–TB model that has streamlined care for co-infected 
patients and decreased mortality.
Table 2 Clinical characteristics of  HIV associated lym-
phoma patients
HAART anti-retroviral therapy, TB tuberculosis, HL Hodgkin’s lymphoma, NHL 
non Hodgkin’s lymphoma, EPTB extra pulmonary tuberculosis, PTB pulmonary 
tuberculosis
Lymphoma type, ART and TB status n %
Documented lymphoma type
 HL 64 35
 NHL 119 65
 Total 183 100.0
HAART
 No 63 34.4
 Yes 120 65.4
 Total 183 100.0
Lymphoma stage
 Stage I 7 3.8
 Stage II 34 18.6
 Stage III 71 38.8
 Stage IV 71 38.8
Total 183 100.0
Site of TB
 EPTB 51 85.0
 PTB 9 15.0
 Total 60 100.0
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Our retrospective design and tertiary care setting, 
would have led to an underestimation of the true rate of 
misdiagnosis as some patients may have died or been lost 
to follow-up before being referred to the UCI. Data was 
collected using non-standardized clinical notes extracted 
from medical charts which potentially lead to recording 
bias, selection bias and missing data. Despite these limi-
tations, we feel that our findings send an important mes-
sage to clinicians managing patients empirically treated 
with TB, especially EPTB to be alert from the beginning 
to the possibility of an alternative diagnosis of HIV asso-
ciated lymphoma.
This study showed a co-morbidity rate of lymphoma 
and TB to be 6.7%, which is consistent with a study by 
De La Rosa et al. [12] that showed a co-occurrence of 6%. 
Therefore, clinicians have to consider an additional as 
well as alternative diagnosis if the response to either lym-
phoma or TB treatment is not achieved.
Conclusion
A high proportion of patients with HIV associated 
lymphoma attending UCI are possibly misdiagnosed 
and treated as TB. Chest pain and stage III and IV 
of lymphoma were associated with a risk of possible 
Table 3 Comparison of characteristics between possible misdiagnosis and definitive diagnosis
No association with Gender, Marital status, Education and Body mass index
HAART anti-retroviral therapy, LDH lactate dehydrogenase, IQR inter quartile range
Characteristics No misdiagnosis n (%) Misdiagnosis n (%) P-value
Fever
 No 32 (86.5) 5 (13.5)
 Yes 95 (65.1) 51 (34.9) 0.012
Chest pain
 No 107 (78.1) 30 (21.9)
 Yes 18 (40.9) 26 (59.1) 0.001
Drenching night sweats
 No 32 (88.9) 4 (11.1)
 Yes 95 (64.6) 52 (35.4) 0.005
Loss of appetite
 No 32 (86.5) 5 (13.5)
 Yes 93 (65.0) 50 (35.0) 0.012
Dyspnea
 No 104 (74.3) 36 (25.7)
 Yes 23 (53.5) 20 (46.5) 0.010
HAART status
 No 49 (77.8) 14 (22.2)
 Yes 78 (65.0) 42 (35.0) 0.075
Stage of lymphoma
 Stage I and II 36 (87.8) 5 (12.2)
 Stage III and IV 91 (64.1) 51 (35.9) 0.004
Cough
 No 84 (72.4) 32 (27.6)
 Yes 43 (64.2) 24 (35.2) 0.240
Lymph node swelling
 No 12 (75.0) 4 (25.0)
 Yes 113 (70.9) 48 (29.8) 0.680
Median (IQR) Median (IQR)
HAART duration (months) duration (months) duration (months) 24 (8–36) 12 (4–36) 0.020
CD4 count 275 (146–458) 172 (96–234) 0.001
Hemoglobin 10.5 (9–12.4) 9.8 (7.1–11.3) 0.020
LDH value 462 (319–721) 468 (263–845) 0.880
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misdiagnosis of lymphoma as TB. Clinicians treating HIV 
patients for TB should have a low threshold for investi-
gating lymphoma.
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Table 4 Multivariate analysis for  possible misdiagnosis 
of HIV associated lymphoma patients
Characteristics Crude odds P-value Adjusted odds P-value
Chest pain
 No 1.00 1.00
 Yes 3.3 (1.46–7.46) 0.004 4.4 (1.89–10.58) 0.001
Stage of lymphoma
 Stage I and II 1.00 1.00
 Stage III and IV 4.03 (1.49–
10.93)
0.006 3.22 (1.08–9.63) 0.037
Drenching night sweats
 No 1.00 1.00
 Yes 4.41 (1.45–3.37) 0.008 1.44 (0.39–5.24) 0.585
Loss of appetite
 No 1.00 1.00






 No 1.00 1.00
 Yes 2.46 (1.01–5.97) 0.010 1.31 (0.56–3.04) 0.535 
Highly Active Anti‑retroviral Therapy status
 No 1.00 1.00
 Yes 1.88 (0.93–3.8) 0.070 1.82 (0.82–4.09) 0.142
Fever
 No 1.00 1.00
 Yes 3.62 (1.31–
10.01)
0.016 1.46 (0.41–5.23) 0.563
 Hemoglobin 0.88 (0.78–0.99) 0.034 0.94 (0.82–1.07) 0.344
